IN8bio’s (INAB) Buy Rating Reiterated at HC Wainwright

IN8bio (NASDAQ:INAB)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $8.00 price target on the stock.

IN8bio Trading Down 4.5 %

Shares of INAB stock opened at $0.30 on Tuesday. The company has a market cap of $21.47 million, a P/E ratio of -0.39 and a beta of -0.07. IN8bio has a fifty-two week low of $0.22 and a fifty-two week high of $2.48. The stock has a 50 day simple moving average of $0.30 and a two-hundred day simple moving average of $0.63. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84.

IN8bio (NASDAQ:INAB) last released its earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Research analysts forecast that IN8bio will post -0.56 earnings per share for the current year.

Hedge Funds Weigh In On IN8bio

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp boosted its position in IN8bio, Inc. (NASDAQ:INAB) by 42.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 851,280 shares of the company’s stock after acquiring an additional 251,600 shares during the period. Sigma Planning Corp owned 1.82% of IN8bio worth $230,000 as of its most recent SEC filing. 92.05% of the stock is currently owned by hedge funds and other institutional investors.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.